GoodRx Holdings, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Wendy Barnes
- Full Time Employees
- 697
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 2701 Olympic Boulevard Santa Monica CA United States of America 90404
- IPO Date
- Sep 23, 2020
- CIK
- 0001809519
- Website
- goodrx.com
- Similar Companies
- Business
- GoodRx Holdings, Inc. (GDRX) operates a leading digital healthcare platform in the United States that provides prescription price comparison, discount coupons, and access to negotiated pricing across more than 75,000 pharmacies; its core offerings include the prescription marketplace with transaction services from pharmacy benefit managers (PBMs), supplemental subscriptions like GoodRx Gold, telehealth consultations via GoodRx Care at a flat fee regardless of insurance, medical testing services, and pharma manufacturer solutions such as co-pay cards, patient assistance programs, and care portals. The Santa Monica, California-based company, founded in 2011, generates revenue primarily from PBM partnerships managing formularies and pricing, pharma manufacturer advertising integrated into its platform, subscription fees, and telehealth visits on a cash-pay basis; it serves consumers, healthcare professionals, payers, PBMs, manufacturers, and retail pharmacies nationwide, with deep relationships including Walgreens, Walmart, CVS Caremark, Publix, Express Scripts, MedImpact, Affirm, and DoorDash for enhanced savings and flexibility. Recent developments include a 2025 collaboration with Novo Nordisk to offer Ozempic and Wegovy at $499 per month for self-paying patients across over 70,000 pharmacies, an expanded partnership with Kroger to deploy the RxSmartSaver program for discounted branded drugs including GLP-1 weight loss medications at 2,200 pharmacies in 35 states, a new partnership with Amgen for Repatha at nearly 60% off list price, potential alignment with TrumpRx initiatives for direct-to-consumer drug discounts, the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions from Amazon Pharmacy in July 2025 to bolster manufacturer partnerships, and projected 35% growth in manufacturer solutions for 2025 amid Q3 2025 revenue beats driven by this segment.
GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call
GoodRx (GDRX) Upgraded to Buy: What Does It Mean for the Stock?
GDRX or HQY: Which Is the Better Value Stock Right Now?
Is GoodRx (GDRX) Stock Undervalued Right Now?
GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs
GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs
3 Reasons Retirees Should Reconsider Enrolling in a Standalone Medicare Drug Plan in 2026
GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade)
GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript
Big Pharma Runs Its Checkout Counter Through GoodRx
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates
GoodRx Reports First Quarter 2026 Results
GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients
Hims & Hers Expands Digital-First Access to Personalized Healthcare
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy?
GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call
GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market
GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price